The abstract is read at the publisher; the summary is JClub's.
Chemotherapy-refractory high-grade serous ovarian carcinoma shows lower type-I interferon and EMT balance scores in a single-cell cohort of nine libraries, with a small hypoxia increase.
- Why it matters: Chemotherapy refractoriness in HGSC may reflect pre-existing tumor-cell states and microenvironmental heterogeneity, but public single-cell signals need careful, context-aware interpretation.
- What they did: Reanalyzed GSE300897 (19,156 cells) from nine treatment-naïve HGSC biopsy libraries (four refractory, five sensitive) and compared program scores with TCGA-OV (421 tumors); also linked MRI to TCGA-24-1423 and tested cisplatin (5 μM, 24 h) in OVCAR-3 and Caov-3 by RT-qPCR.
- The result: No cancer-cell program met BH q < 0.05 across GSE300897; in TCGA-OV, IFN-I tertiles separated survival nominally (log-rank p = 0.029) while adjusted continuous IFN-I was not significant (HR = 0.96 per SD, BH q = 0.927), and cisplatin lowered IFIT1/MX1 and raised SNAI1/HIF1A (Holm-adjusted p < 0.05).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.